Spiros Arbes, MD
Nephrology · Eatontown, NJNPI 1215943592
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,452 of the $8,813 with a category attached, or 73.2%. 31 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 26.8% of the total. Reporting peaked in 2019 at $3,012 and has fallen 61.1% since, to $1,171 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Amgen$729
- OPKO Pharmaceuticals, LLC$725
- Aurinia Pharma U.S., Inc.$652
- AstraZeneca$633
- Bayer$587
- plus $3K from 25 others
What the payments were for
- Consulting fees$2,08824%
- Travel & lodging$821%
- Food & beverage$6,45273%
- Education$1912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $2,358 |
| Amgen(2 entities) | 43 | $729 |
| OPKO Pharmaceuticals, LLC | 33 | $725 |
| Aurinia Pharma U.S., Inc. | 22 | $652 |
| AstraZeneca | 30 | $633 |
| Bayer | 38 | $587 |
| Vifor Pharma, Inc. | 30 | $528 |
| Fresenius USA Marketing, Inc. | 21 | $331 |
| Arbor Pharmaceuticals, Inc. | 34 | $328 |
| GSK | 18 | $270 |
| Mallinckrodt Hospital Products Inc. | 12 | $174 |
| Boehringer Ingelheim | 9 | $148 |
| Mallinckrodt Enterprises LLC | 4 | $143 |
| Amarin Pharma, Inc. | 10 | $141 |
| Calliditas Therapeutics US Inc. | 7 | $119 |
| Akebia Therapeutics Inc | 10 | $117 |
| Ardelyx, Inc. | 6 | $108 |
| Novartis | 6 | $98 |
| Travere Therapeutics, Inc. | 6 | $91 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $90 |
| Lundbeck LLC | 5 | $75 |
| Nxstage Medical, Inc. | 2 | $75 |
| Daiichi Sankyo Inc. | 5 | $74 |
| Novo Nordisk | 3 | $48 |
| ANI Pharmaceuticals, Inc. | 3 | $48 |
| Lilly USA, LLC | 2 | $32 |
| Strongbridge US Inc. | 2 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,813 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 38 | $52,660 |
| VeltassaPatiromer Calcium Sorbitex | 41 | $52,255 |
| JardianceEmpagliflozin | 31 | $45,564 |
| FarxigaDapagliflozin Propanediol | 64 | $44,989 |
| RayaldeeCalcifediol | 39 | $26,013 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $15,053 |
| JanuviaSitagliptin Phosphate | 12 | $6,619 |
| Nebivolol Hcl | 73 | $4,630 |
| Droxidopa | 14 | $3,338 |
| Paricalcitol | 25 | $2,134 |
| Ethacrynic Acid | 11 | $1,777 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,773 |
| Sevelamer Carbonate | 20 | $1,753 |
| Metoprolol Succinate | 69 | $1,480 |
| Amlodipine Besylate | 155 | $1,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $633 | $60,04279 claims |
| BayerKerendia | $587 | $52,66038 claims |
| Boehringer IngelheimJardiance | $148 | $45,56431 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $725 | $26,01339 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $48 | $1,11225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Eatontown
- Kenneth LissEatontown$75K
- Noel NiveraEatontown$8K
- Alan HaratzEatontown$8K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Jeffrey GoodmanFlorham Park$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.